Scientists have detected resistance to artemisinin, a key malaria drug, for the first time among children in Africa with ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

However, production of the mRNA used in vaccines is hindered by its ... Oct. 23, 2024 — Maternal antibodies passed across the placenta can interfere with the response to the malaria vaccine ...

The continent is being drenched in an avalanche of medical disinformation with the aim of undermining western influence ...

showing very encouraging results and paving the way for future malaria vaccine development. A robust industrial partner, GSK Biologicals, has shown commitment to the project for more than 20 years ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...

Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...

EMVI = European malaria vaccine initiative; GLURP = Glutamate-rich protein; GSK = GlaxoSmithKline; LSA = Liver-stage antigen; LSP = Long-synthetic peptide; ME-TRAP = Multiepitope-thrombospondin ...

pharmaphorum is pleased to interview here Dr Sophie Biernaux who serves as head of the Malaria Vaccine Franchise for GlaxoSmithKline Vaccines, where she leads the company's research and ...

US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...